FrancophonIA/ELRC3.0 huggingface dataset:
English: A subset of approximately 12 % of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.
Maltese: Subset ta' madwar 12 % tal-pazjenti li fil-linja bażi kellhom evalwazzjonijiet ċitoġenetiċi normali, sussegwentement instab li kellhom anormalitajiet, fosthom monosomy 7, f'evalwazzjoni tas-soltu li ġiet ripetuta.
English: Astheniaa Malaisee Oedema peripherale
Maltese: Edima periferalie
English: Myelodysplastic syndrome or Chronic myeloid leukemia
Maltese: Sindrome majelodisplastika jew Lewkimja majeloġenika kronika
English: Transformation to leukaemia or myelodysplastic syndrome
Maltese: (lewkimja, sindrome mijelodisplastiku [MDS - myelodysplastic syndrome]).
English: Oropharyng eal paina,e
Maltese: Ġie nnutat li t-tnaqqis fid-doża ta'
English: Discontinuation of filgrastim therapy usually results in a 50 % decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.
Maltese: Il-waqfien mill-kura ta' filgrastim is-soltu jġib tnaqqis ta' 50% tan-newtrofili fid-demm fiż żmien ġurnata jew tnejn, b'ritorn għall-livelli normali fiż-żmien 1 sa 7 ijiem.
English: There is no evidence that patients with HIV infection treated with filgrastim show an increase in HIV replication.
Maltese: M'hemmx evidenza li pazjenti b'infezzjoni ta' HIV ikkurati b'filgrastim ikollhom żieda fir replikazzjoni ta' HIV.
English: Other medicines and Ratiograstim
Maltese: Mediċini oħra u Ratiograstim
English: There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.4 and 5.1).
Maltese: Kien hemm rapporti ta' GvHD u mwiet f'pazjenti li kienu qed jirċievu G-CSF wara trapjant alloġeniku tal-mudullun (ara sezzjonijiet 4.4 u 5.1). d.
English: Congenital neutropenia
Maltese: Newtropenja konġenitali
English: In view of the possible risk of microbial contamination, Ratiograstim syringes are for single use only.
Maltese: Minħabba r-riskju potenzjali ta' kontaminazzjoni bil-mikrobi, is-siringi ta' Ratiograstim iridu jintużaw darba biss.
English: Ratiograstim 30 MIU/0.5 mL solution for injection/infusion Filgrastim
Maltese: Ratiograstim 30 MIU/0.5 mL soluzzjoni għall-injezzjoni/infużjoni Filgrastim
English: Ratiograstim 48 MIU/0.8 mL: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL solution.
Maltese: Kull siringa mimlija għal-lest fiha 48 miljun international units [MIU] (480 mikrogrammi) filgrastim f'0.8 mL (60
English: Each mL of solution for injection/infusion contains 60 million international units [MIU] (600 microgram) of filgrastim.
Maltese: Kull mL ta' soluzzjoni għall-injezzjoni/infużjoni fiha 60 miljun international units [MIU] (600 mikrogramma) ta' filgrastim.
English: Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post marketing experience.
Maltese: Reazzjonijiet ta' sensittività eċċessiva, inklużi anafilassi, raxx, urtikarja, anġjoedima, qtugħ ta' nifs u pressjoni baxxa, li seħħew waqt trattament tal-bidu jew trattament sussegwenti, ġew irrappurtati fi studji kliniċi u fl-esperjenza ta' wara t-tqegħid fis-suq.
English: In patients with severe chronic neutropenia (SCN) Posology
Maltese: F'pazjenti b'newtropenja kronika u qawwija (SCN)
English: Ratiograstim is a biosimilar medicinal product.
Maltese: L03AA02 Ratiograstim hu prodott mediċinali bijoloġiku simili.
English: The efficacy and safety of Ratiograstim has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma.
Maltese: III, randomised u kontrollati bi placebo, f'pazjenti b'kanċer tas-sider, kanċer tal-pulmun u Non-Hodgkin-Limfoma.
English: Congenital, idiopathic or cyclic neutropenia:
Maltese: Newtropenija konġenitali, idjopatika jew ċiklika:
English: Solution for injection/infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.5 mL.
Maltese: Pakkett multiplu: 10 (2 pakketti ta' 5) siringi mimlija għal-lest b'0.5 mL.
English: Packs containing 1, 5 or 10 pre-filled syringes with 0.8 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.8 mL solution.
Maltese: Pakketti li fihom 1, 5 jew 10 siringi mimlija għal-lest b'0.8 mL ta' soluzzjoni jew pakketti multipli li fihom 10 (2 pakketti ta' 5) siringi mimlija għal-lest b'0.8 mL ta' soluzzjoni.
English: Do not administer filgrastim to patients with a history of hypersensitivity to filgrastim or pegfilgrastim
Maltese: Tagħtix filgrastim lil pazjenti bi storja medika ta' sensittività eċċessiva għal filgrastim jew pegfilgrastim.
English: The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea.
Maltese: L-aktar reazzjonijiet avversi rrappurtati b'mod komuni huma deni, uġigħ muskoluskeletriku (li jinkludi uġigħ fl-għadam, uġigħ fid-dahar, artralġja, mijalġja, uġigħ f'estermitajiet, uġigħ muskoluskeletriku, uġigħ muskoluskeletriku fis-sider, uġigħ fl-għonq), anemija, rimettar u dardir.
English: Ratiograstim 48 MIU/0.8 mL solution for injection/ infusion Filgrastim
Maltese: Ratiograstim 48 MIU/0.8 mL soluzzjoni għall-injezzjoni/infużjoni Filgrastim
English: The onset of pulmonary signs such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome (ARDS).
Maltese: Il-bidu ta' sinjali pulmonari bħal sogħla, deni u qtugħ ta' nifs flimkien ma' sinjali radjuloġiċi ta' infiltrati pulmonari u deterjorazzjoni tal-funzjoni tal-pulmun jistgħu jkunu sinjali tal-bidu tas-sindrome ta' diffikultà respiratorja akuta (ARDS - acute respiratory distress syndrome).
English: How do I prepare my Ratiograstim injection?
Maltese: Kif nipprepara l-injezzjoni ta' Ratiograstim?
English: Intravenous (80 µg/kg/day) administration of filgrastim to rabbits during the period of organogenesis was maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and foetal weight were observed.
Maltese: L-għoti fil-vini (80 μg/kg/jum) ta' filgrastim lill-fniek waqt il-perjodu ta' organoġenesi kien tossiku għall-omm u kienu osservati żieda fl-abort spontanju, fit-telf wara l-impjantazzjoni u tnaqqis fid-daqs medju talboton ħaj u fil-piż tal-fetu.
English: Hypotensio n
Maltese: ANNESS II
English: TRM
Maltese: Ftakar
English: 1 pre-filled syringe containing 0.8 mL 1 pre-filled syringe with safety device containing 0.8 mL 5 pre-filled syringes containing 0.8 mL 5 pre-filled syringes with safety device containing 0.8 mL 10 pre-filled syringes containing 0.8 mL
Maltese: 1 siringi mimlija għal-lest bi protezzjoni għas-sigurtà tal-labra b'0.8 mL 5 siringi mimlija għal-lest b'0.8 mL
English: Splenomegaly and Splenic rupture
Maltese: Splenomega lijaa
English: If more than one leukapheresis is required, particular attention should be paid to donors with platelets < 100 x 109/L prior to leukapheresis; in general apheresis should not be performed if platelets < 75 x 109/L.
Maltese: Jekk ikun hemm bżonn ta' iktar minn proċedura waħda ta' lewkafereżi, għandha tingħata attenzjoni partikulari lil donaturi b'livell ta' plejtlits ta' < 100 x 109/L qabel il-lewkafereżi; bħala regola ġenerali, afereżi m'għandiex issir jekk il-livell ta' plejtlits ikun < 75 x 109/L.
English: Blood alkaline phosphatase increased
Maltese: alkaline Phosphatase fid-demm
English: In a separate retrospective international study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen.
Maltese: Fi studju internazzjonali retrospettiv separat f'pazjenti b'lewkimji majeloġeni akuti u kroniċi, ma ġie osservat l-ebda effett fuq ir-riskju ta' GvHD, TRM u lmortalità.
English: Urine abnormality
Maltese: Anormalità tal-awrina
English: Accidental exposure to freezing temperatures does not adversely affect the stability of Ratiograstim.
Maltese: L-esposizzjoni bi żball għal temperatura ta' friża ma jeffettwax ħażin l-istabilita` ta' Ratiograstim.
English: White blood cell counts of 100 x 109/L or greater have been observed in less than 5 % of cancer patients receiving filgrastim at doses above 0.3 MIU/kg/day (3 μg/kg/day).
Maltese: Għadd taċ-ċelluli bojod ta' 100 x 109/L jew aktar ġew osservati f'inqas minn 5 % tal-pazjenti bilkanċer li ngħataw filgrastim b'dożi akbar minn 0.3 MIU/kg/jum (3 μg/kg/jum).
English: Paediatric SCN patients
Maltese: PROPRJETAJIET FARMAKOLOĠIĊI 5
English: Ratiograstim containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Maltese: Ratiograstim, li fih r-metHuG-CSF (filgrastim), jikkawża żjieda sinifikanti fl-għadd ta' newtrofili fid-demm periferali fi żmien 24 siegħa, b'żjidiet minuri fil-monoċiti.
English: Special precautions in patients undergoing PBPC mobilisation Mobilisation
Maltese: Prekawzjonijiet speċjali f'pazjenti taħt proċedura ta' mobilizzazzjoni ta' PBPC
English: Solution for injection/infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.8 mL.
Maltese: Pakkett multiplu: 10 (2 pakketti ta' 5) siringi mimlija għal-lest b'0.8 mL
English: Haemoptysi s
Maltese: Iperurikemij a
English: In cancer patients, the pharmacokinetic profile of Ratiograstim and the reference product was comparable after single and repeated subcutaneous administration.
Maltese: F'pazjenti b'kanċer, il-profil farmacokinetiku ta' Ratiograstim u dak tal-prodott ta' referenza kienu komparabbli wara amministrazzjoni taħt il-ġilda ta' doża waħda jew dożi ripetuti.
English: Splenomega lya
Maltese: Għejaa
English: How long will I have to take Ratiograstim?
Maltese: Għal kemm żmien għandi nieħu Ratiograstim?
English: Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥ 20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).
Maltese: Frieħ ta' firien mogħtija filgrastim waqt il-perjodi ta' madwar it-twelid u t-treddigħ, urew ittardjar fiddifferenzjazzjoni esterna u fit-tkabbir (> 20 μg/kg/jum) u rata ta' sopravivenza kemxejn imnaqqsa (100 μg/kg/jum.
English: Permanently discontinue Ratiograstim in patients with clinically significant hypersensitivity.
Maltese: Waqqaf Ratiograstim għal kollox f'pazjenti b'sensittività eċċessiva li hija klinikament sinifikanti.
English: Cutaneous vasculitisa
Maltese: Kimoterapija ċitotossika stabbilita
English: • bleeding from the lung (pulmonary haemorrhage)
Maltese: • infjammazzjoni tal-pulmun (marda tal-interstizju tal-pulmun)
English: 1 pre-filled syringe containing 0.5 mL 1 pre-filled syringe with safety device containing 0.5 mL 5 pre-filled syringes containing 0.5 mL 5 pre-filled syringes with safety device containing 0.5 mL 10 pre-filled syringes containing 0.5 mL
Maltese: 5 siringi mimlija għal-lest bi protezzjoni għas-sigurtà tal-labra b'0.5 mL 10 siringi mimlija għal-lest b'0.5 mL
English: Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy suggesting no age-related differences in the pharmacokinetics of filgrastim.
Maltese: Data minn studji kliniċi f'pazjenti pedjatriċi juru li s-sigurtà u l-effikaċja ta' filgrastim huma simili kemm fl-adulti kif ukoll fit-tfal li jirċievu kimoterapija ċitotossika, li tissuġġerixxi li m'hemm l-ebda differenza marbuta mal-età fil-farmakokinetika ta' filgrastim.
English: Vascular disorders
Maltese: Disturbi respiratorji
English: Statistical analysis of the relationship between the number of CD34+ cells re-infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship.
Maltese: Analiżi statistika tar-relazzjoni bejn in-numru ta' ċelluli CD34+ infużi mill-ġdid u r-rata ta' rkupru tal plejtlits wara kimoterapija ta' doża għolja jindika relazzjoni kumplessa iżda kontinwa.
English: How to store Ratiograstim
Maltese: X'fih Ratiograstim
English: Cases of decreased bone density and osteoporosis have been reported in paediatric patients with SCN receiving chronic treatment with filgrastim.
Maltese: Każijiet ta' tnaqqis fid-densità tal-għadam u ta' osteoporożi ġew irrappurtati f'pazjenti pedjatriċi b'SCN li kienu qed jirċievu trattament kroniku b'filgrastim.
English: Transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim administration and leukapheresis was observed in 35 % of subjects studied.
Maltese: (plejtlits < 100 x 109/L) f'35 % tal-individwi li ġew studjati.
English: How to use Ratiograstim
Maltese: X'inhu Ratiograstim
English: Cutaneous vasculitis
Maltese: Sturdament Ipoestesija
English: Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.
Maltese: Mobilizzazzjoni ta' PBPC ma tipprovdix benefiċju kliniku dirett għal donaturi normali u għandha tiġi ikkunsidrata biss għal skop ta' trapjant alloġeniku ta' ċelluli staminali.
English: In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Ratiograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Maltese: F'pazjenti, tfal jew adulti, li għandhom newtropenja severa, konġenita, ċiklika, jew idjopatika bl-Għadd Assolut ta' Newtrofili (ANC) ta' ≤ 0.5 x 109/L, u storja ta' infezzjonijiet qawwija jew li jirkadu, it-terapija fit-tul b'Ratiograstim huwa indikat biex jiżdied l-għadd ta' newtrofili u sabiex l-inċidenza u t-tul ta' ġrajjiet avversi relatati ma' infezzjonijiet jonqsu.
English: Donors who receive G-CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.
Maltese: Donaturi li jirċievu G-CSFs għal mobilizzazzjoni ta' PBPC għandhom jiġu mmonitorjati sakemm ilparametri ematoloġiċi jerġgħu lura għan-normal.
English: 1995-2000b aAnalysis includes studies involving bone marrow transplant during this period; some studies used GM-CSF (granulocyte-macrophage-colony stimulating factor) bAnalysis includes patients receiving bone marrow transplant during this period
Maltese: 1995-2000b aL-analiżi tinkludi studji li jinvolvu trapjant tal-mudullun matul dan il-perjodu; xi studji użaw GM-CSF
English: Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight.
Maltese: Il-proċedura ta' lewkafereżi trid tibda fil-5 ġurnata u titkompla sas-6 ġurnata jekk ikun hemm bżonn sabiex jinġabru 4 x 106 CD34+ celluli għal kull kg ta' piż tal-ġisem tar-riċevitur.
English: Marketing Authorisation Holder ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm
English: PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.
Maltese: Mobilizzazzjoni ta' PBPC għandha tiġi kkunsidrata biss f'donaturi li jissodisfaw il-kriterji kliniċi u tal-laboratorju normali ta' eliġibilità għal donazzjoni ta' ċelluli steminali b'attenzjoni speċjali lejn ilvaluri ematoloġiċi u mard infettiv.
English: Each pre-filled syringe contains 48 MIU (480 µg) of filgrastim in 0.8 mL solution for injection/infusion.
Maltese: Kull siringa mimlija għal-lest fiha 48 MIU (480 µg) filgrastim f'0.8 mL ta' soluzzjoni għall injezzjoni/infużjoni.
English: • severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)
Maltese: • uġigħ sever fl-għadam, fis-sider, fl-imsaren jew fil-ġogi (anemija taċ-ċelluli Sickle bi kriżi)
English: The recommended starting dose of filgrastim is 1.0 MIU (10 μg)/kg/day.
Maltese: MIU (10 μg)/kg/jum.
English: Granulocyte-colony stimulating factor can promote growth of myeloid cells in vitro and similar effects may also be seen on some non-myeloid cells in vitro.
Maltese: Tumur malinn Il-fattur li jistimula l-kolonji ta' granuloċiti (Granulocyte-colony stimulating factor) jista' jippromwovi it-tkabbir ta' ċelluli majelojdi in vitro u effetti simili jistgħu jidhru wkoll f'xi ċelluli mhux majelojdi in vitro.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Wrapper Label on Multipacks- With Blue Box
Maltese: It-tikketta ta' fuq il-kisja ta' barra fuq pakketti multipli miksijin filfojl trasparenti b'kaxxa ċelesti
English: Ratiograstim does not contain any preservative.
Maltese: Ratiograstim ma fih l-ebda preservattiv.
English: Each pre-filled syringe contains 30 MIU (300 µg) of filgrastim in 0.5 mL solution for injection/infusion.
Maltese: Kull siringa mimlija għal-lest fiha 30 MIU (300 µg) filgrastim f'0.5 mL ta'soluzzjoni għall injezzjoni/infużjoni.
English: Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50 % within 1 to 2 days, and to normal levels within 1 to 7 days.
Maltese: filgrastim, l-għadd ta' newtrofili fid-demm jonqos b'50% fiż-żmien ġurnata 1 jew 2, b'ritorn għall-livelli normali fiż-żmien 1 sa 7 ijiem.
English: Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 x 109/L.
Maltese: Filgrastim irid jingħata ta' kuljum bħala injezzjoni taħt il-ġilda sakemm l-għadd ta' newtrofili jilħaq u jinżamm il-fuq minn 1.5 x 109/L.
English: Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.
Maltese: Data attwali tindika li l-interazzjonijiet immunoloġiċi bejn trapjant alloġeniku ta' PBPC u r-reċipjent jistgħu jkunu assoċjati ma' riskju ogħla ta' GvHD akuta u kronika meta kkomparat ma' trapjant talmudullun.
English: Subsequently the dose may be individually adjusted every 1 to 2 weeks to maintain the average neutrophil count between 1.5 x 109/L and 10 x 109/L.
Maltese: tiġi aġġustata għal individwu kull gimgħa jew gimgħatejn biex il-medju tal-għadd ta' newtrofili jinżamm bejn 1.5 x 109/L u 10 x 109/L.
English: Neutropenia may be due to bone marrow infiltrating opportunistic infections such as Mycobacterium avium complex or malignancies such as lymphoma.
Maltese: In-newtropenija tista' tkun ikkawżata minn infezzjonijiet opportunistiċi li jinfiltraw il-mudullun bħall kumpless Mycobacterium avium jew mard malinn bħal limfoma.
English: During intermittent dosing with 30 MIU (300 μg)/day of filgrastim, there can be wide fluctuations in the patient's ANC over time.
Maltese: Waqt dożaġġ intermittenti b'dożi ta' 30 MIU (300 μg)/jum ta' filgrastim, l-ANC tal-pazjent jista' jvarja ħafna maż-żmien.
English: Fluid volume disturbances
Maltese: Disturbi vaskulari
English: For patients treated with filgrastim diluted to concentrations below 1.5 MIU (15 μg) per mL, human serum albumin (HSA) should be added to a final concentration of 2 mg/mL.
Maltese: MIU (15 μg)/mL, din trid tiġi miżjuda blalbumina tas-serum umana (HSA) sabiex il-konċentrazzjoni finali tkun 2 mg/mL.
English: Pharmacotherapeutic group: Immunostimulants, colony stimulating factors, ATC code: L03AA02
Maltese: Immunostimulanti, fatturi li jistimolaw il-kolonji ta' granuloċiti,
English: • high uric acid levels in the blood, which may cause gout (hyperuricaemia) (blood uric acid increased)
Maltese: • livelli għoljin ta' aċidu uriku fid-demm, li jistgħu jikkawżaw gotta (iperurikemija) (żieda ta'
English: Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products.
Maltese: Trattament b'filgrastim waħdu ma' jipprekludix l-iżvilupp ta' tromboċitopenija u anemija kkawżati minn prodotti mediċinali mijelosoppressivi.
English: Ratiograstim is supplied in packs of 1, 5 or 10 pre-filled syringes or multipacks of 10 (2 packs of 5) pre-filled syringes.
Maltese: Ratiograstim jiġi f'pakketti ta' 1, 5 jew 10 siringi mimlijin għal-lest jew f'pakkett multiplu ta'10 (2
English: Solution for injection/infusion 5 pre-filled syringes containing 0.5 mL.
Maltese: U KONTENUT Soluzzjoni għall-injezzjoni/infużjoni 1 siringa mimlija għal-lest b'0.5 mL
English: The additive effect of concomitantly given products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.
Maltese: L-effett addittiv ta' prodotti li jkun fihom sorbitol (jew fructose) mogħtija fl-istess waqt u t-teħid ta' sorbitol (jew fructose) fid-dieta għandu jiġi kkunsidrat.
English: Pulmonary haemorrhag e
Maltese: Epatomegal ija
English: There were no relevant differences between Ratiograstim and the reference product with regard to duration of severe neutropenia and incidence of febrile neutropenia.
Maltese: Ma kienx hemm differenzi rilevanti bejn Ratiograstim u l-prodott ta' referenza fir-rigward ta' dewmien ta' newtropenja qawwija u l-inċidenza ta' newtropenja bid-deni.
English: The recommended starting dose is 1.2 MIU (12 μg)/kg/day as a single dose or in divided doses.
Maltese: Id-doża tal-bidu rakkomandata hi 1.2 MIU (12 μg)/kg/jum bħala doża waħda jew f'dożi maqsumin.
English: Treatment with filgrastim significantly reduces the duration of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation.
Maltese: Mhux magħruf jekk filgrastim/metaboliti jiġux eliminat mill-ħalib tas-sider tal-bniedem.
English: For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation
Maltese: Għall-mobilizzazzjoni ta' PBPCs f'pazjenti taħt kura majelosoppressiva jew majeloablativa segwit bit-trapjant awtolgu ta' PBPC
English: Psychiatic diorders
Maltese: TAL-PRODOTT MEDIĊINALI
English: Prior exposure to cytotoxic agents
Maltese: KONDIZZJONIJIET U REKWIŻITI OĦRA TAL-AWTORIZZAZZJONI
English: Leukocytosi sa
Maltese: Il-pazjenti kollha
English: Haemoglobi n decreasede
Maltese: Marda tatTrapjant kontra lOspitub
English: The use of filgrastim mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Maltese: Tromboċitopenija ġiet irrappurtata f'pazjenti li kienu qed jirċievu filgrastim.
English: Venoocclusive diseased
Maltese: Marda venookklussivad
English: • Inflammation of aorta (the large blood vessel which transports blood from the heart to the body), see section 2
Maltese: • infjammazzjoni tal-aorta (l-arterja l-kbira tad-demm li tittrasporta d-demm mill-qalb għall ġisem), ara sezzjoni 2
English: To give yourself a subcutaneous injection you will need: - a pre-filled syringe of Ratiograstim; - alcohol wipes or similar; - a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
Maltese: - msielaħ tal-alkoħol jew simili; - reċipjent li ma jitaqqabx (reċipjent tal-plastik li jinkiseb min sptar jew spiżerija) sabiex tarmi is siringi fis-sigurta'.
English: Headachea
Maltese: Treddigħ
English: Ratiograstim is one of a group of products that stimulate the production of white blood cells.
Maltese: Ratiograstim huwa wieħed mill-gruppi ta' prodotti li jistimulaw il-produzzjoni ta' ċelluli bojod tad demm.